Download Overcoming Cancers Resistant To Her 2 Antibodies Book PDF

Download full Overcoming Cancers Resistant To Her 2 Antibodies books PDF, EPUB, Tuebl, Textbook, Mobi or read online Overcoming Cancers Resistant To Her 2 Antibodies anytime and anywhere on any device. Get free access to the library by create an account, fast download and ads free. We cannot guarantee that every book is in the library.

Overcoming Cancers Resistant to Her-2 Antibodies

Overcoming Cancers Resistant to Her-2 Antibodies
  • Author : Benjamin Bonavida
  • Publisher :Unknown
  • Release Date :2019-12-15
  • Total pages :250
  • ISBN : 0128164085
GET BOOK HERE

Summary : Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Therefore, the use of various immunosensitizing agents to reverse resistance has been considered and this book discusses each of them in depth, such as Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Targeted Therapies in Breast Cancer

Targeted Therapies in Breast Cancer
  • Author : George W. Sledge, Jr.,Jose Baselga
  • Publisher :Unknown
  • Release Date :2013-04-15
  • Total pages :100
  • ISBN : 1846920663
GET BOOK HERE

Summary : This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer
  • Author : Benjamin Bonavida
  • Publisher :Unknown
  • Release Date :2013-08-04
  • Total pages :202
  • ISBN : 9781461476542
GET BOOK HERE

Summary : ​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Translational Research in Breast Cancer

Translational Research in Breast Cancer
  • Author : Dong-Young Noh
  • Publisher :Unknown
  • Release Date :2021
  • Total pages :229
  • ISBN : 9789813296206
GET BOOK HERE

Summary :

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition

Monoclonal Antibodies—Advances in Research and Application: 2012 Edition
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2012-12-26
  • Total pages :105
  • ISBN : 9781481605168
GET BOOK HERE

Summary : Monoclonal Antibodies—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Monoclonal Antibodies. The editors have built Monoclonal Antibodies—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Monoclonal Antibodies in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Monoclonal Antibodies—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Cancer Research

Cancer Research
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2006-08
  • Total pages :229
  • ISBN : CORNELL:31924101073397
GET BOOK HERE

Summary :

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer
  • Author : Sara Hurvitz,Kelly McCann
  • Publisher :Unknown
  • Release Date :2018-07-26
  • Total pages :264
  • ISBN : 9780323581233
GET BOOK HERE

Summary : Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Targeted Cancer Therapies, From Small Molecules to Antibodies

Targeted Cancer Therapies, From Small Molecules to Antibodies
  • Author : Zhe-Sheng Chen,Jian-ye Zhang,Yunkai Zhang,Yan-yan Yan
  • Publisher :Unknown
  • Release Date :2020-07-22
  • Total pages :229
  • ISBN : 9782889638840
GET BOOK HERE

Summary :

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
  • Author : Goli Samimi,Christina Annunziata
  • Publisher :Unknown
  • Release Date :2020-11-06
  • Total pages :188
  • ISBN : 9780128198414
GET BOOK HERE

Summary : Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher :Unknown
  • Release Date :2019-07-15
  • Total pages :320
  • ISBN : 9783030214777
GET BOOK HERE

Summary : Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Anticancer Research

Anticancer Research
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2008
  • Total pages :229
  • ISBN : UCLA:L0098923790
GET BOOK HERE

Summary :

Her-2

Her-2
  • Author : Robert Bazell
  • Publisher :Unknown
  • Release Date :2011-04-27
  • Total pages :240
  • ISBN : 9780307764980
GET BOOK HERE

Summary : Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.

Breast Cancer Chemosensitivity

Breast Cancer Chemosensitivity
  • Author : Dihua Yu,Mien-Chie Hung
  • Publisher :Unknown
  • Release Date :2009-12-30
  • Total pages :175
  • ISBN : 9780387740393
GET BOOK HERE

Summary : In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem, the book then focuses on the latest findings of molecular mechanisms of drug resistance. Coverage provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. It allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer therapeutic resistance.

Tumor Progression and Therapeutic Resistance

Tumor Progression and Therapeutic Resistance
  • Author : Wafik S. El-Deiry
  • Publisher :Unknown
  • Release Date :2005
  • Total pages :198
  • ISBN : UVA:X030000978
GET BOOK HERE

Summary : This volume presents the entire breadth of translational cancer research and brings together members of academia and industry in the expectation of accelerating interactions and progress in the field. A variety of key topics are presented, beginning with discovery of molecular targets and pathways (oncogene, cell survival, tumor suppression, cell death), host-neoplasm interactions (cell adhesion, matrix proteases), early detection, monitoring progression, understanding tumor progression and metastasis, immune surveillance, in vivo molecular imaging, animal models, drug discovery including chemistry, high-throughput assays, mechanism determination, target validation, therapeutic window and some progress in clinical trials for more advanced agents and targets.

Indian Journal of Medical Research

Indian Journal of Medical Research
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2007
  • Total pages :229
  • ISBN : UCLA:L0098889900
GET BOOK HERE

Summary :

Breast Cancer

Breast Cancer
  • Author : Phuc Van Pham
  • Publisher :Unknown
  • Release Date :2017-04-05
  • Total pages :568
  • ISBN : 9789535129998
GET BOOK HERE

Summary : Breast Cancer - From Biology to Medicine thoroughly examines breast cancer from basic definitions, to cellular and molecular biology, to diagnosis and treatment. This book also has some additional focus on preclinical and clinical results in diagnosis and treatment of breast cancer. The book begins with introduction on epidemiology and pathophysiology of breast cancer in Section 1. In Section 2, the subsequent chapters introduce molecular and cellular biology of breast cancer with some particular signaling pathways, the gene expression, as well as the gene methylation and genomic imprinting, especially the existence of breast cancer stem cells. In Section 3, some new diagnostic methods and updated therapies from surgery, chemotherapy, hormone therapy, immunotherapy, radiotherapy, and some complementary therapies are discussed. This book provides a succinct yet comprehensive overview of breast cancer for advanced students, graduate students, and researchers as well as those working with breast cancer in a clinical setting.

Drug Resistance in Oncology

Drug Resistance in Oncology
  • Author : Beverly A. Teicher
  • Publisher :Unknown
  • Release Date :1993
  • Total pages :654
  • ISBN : UOM:39015029521609
GET BOOK HERE

Summary : This volume focuses on the mechanisms that involve alterations in cellular biochemistry, properties related to the physiology of the solid tumour mass and changes in the host metabolic status induced by the presence of the tumour - applying this information to the resistance to cancer chemotherapy, radiation therapy and biomodulator therapies. angiogenesis and blood-flow, pH, oxygenation, molecular transport and tissue pressure, oncogenes and tumour-suppressor genes, extracellular matrix and phosphate metabolism; discusses clonal subpopulations, resistance in leukimia, the blood brain barrier, tumour/host interactions and the metastatic phenotype; examines glutathione, metallothionein, glutathione-S-transferases, oxazaphosphorane metabolism, cytochrome P-450, multi-drug resistance and nuclear matrix influence; and presents the effects of antioestrogens, chorionic gonadotropin, transforming and fibroblast growth factors, metastases and radiation resistance.

The Biology of Tumors

The Biology of Tumors
  • Author : Enrico Mihich,Carlo Croce
  • Publisher :Unknown
  • Release Date :2013-06-29
  • Total pages :351
  • ISBN : 9781489913524
GET BOOK HERE

Summary : The Ninth Annual Pezcoller Symposium entitled "The Biology of Tumors" was held in Rovereto, Italy, June 4-7, 1997. It focused on the genetic mechanisms underlying het erogeneity of tumor cell populations and tumor cell differentiation, on interactions be tween tumor cells and cells of host defenses, and the mechanisms of angiogenesis. With presentations at the cutting edge of progress and stimulating discussions, this symposium addressed issues related to phenomena concerned with cell regulation and cell interactions as determined by activated genes through the appropriate and timely media tion of gene products. Important methodologies that would allow scientists to measure dif ferentially genes and gene products and thus validate many of the mechanisms of control currently proposed were considered, as were the molecular basis of tumor recognition by the immune system, interactions between cells and molecular mechanisms of cell regula tion as they are affected by or implemented through these interactions. The molecular and cellular mechanisms of tumor vascularization were also discussed. It was recognized that angiogenesis provides a potential site of therapeutic intervention and this makes it even more important to understand the mechanisms underlying it. We wish to thank the participants in the symposium for their substantial contribu tions and their participation in the spirited discussions that followed. We would also like to thank Drs.

Science & Culture

Science & Culture
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2004
  • Total pages :229
  • ISBN : UOM:39015062098689
GET BOOK HERE

Summary :

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab
  • Author : Banujan Balachandran
  • Publisher :Unknown
  • Release Date :2013
  • Total pages :229
  • ISBN : OCLC:922055022
GET BOOK HERE

Summary : "Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab, a humanized monoclonal antibody binding to the extracellular domain of HER-2, has proven to be a beneficial treatment for patients diagnosed as HER-2+ but continues to have limitations. With low response rates for patients when administered alone and for patients having received prior chemotherapy, the true potential of trastuzumab seems to arrive only through combination therapies. However, the majority of advanced HER-2 positive breast cancer patients still develop resistance to the therapy by the end of the first year or present de novo resistance. For this reason, it is important to continue to investigate therapies to give in combination with trastuzumab to improve progression-free survival and overall survival in this clinical setting. Two Phase II Astra Zeneca compounds: AZD0530, a dual Src and Abl kinase inhibitor and AZD8931, a pan-erbb tyrosine kinase inhibitor abrogating EGFR-, HER-2-, and HER-3-mediated signaling were explored in this context using established trastuzumab-naïve and trastuzumab-resistant cell lines. AZD0530 was not effective when administered alone and any combinations with trastuzumab showed positive responses only in those models in which some form of response to AZD0530 alone had been seen. Clinically-relevant responses to AZD8931 were seen in all cell lines tested and for this reason a head-to-head comparison was carried out with lapatinib, the FDA-approved therapy for patients progressing on trastuzumab. AZD8931 alone and in combination with trastuzumab worked effectively to stop proliferation and induce cell death in both trastuzumab-naïve and trastuzumab-resistant cell lines at clinically relevant doses. AZD8931 had similar activity to lapatinib in the SKBR3-based ER-negative cell lines, but was less active in the BT474-based ER-positive cell lines. From this study, it appears AZD8931 is a therapeutic candidate for overcoming trastuzumab resistance but further investigation is required, before translation into the clinical setting, including the use of animal models of trastuzumab-resistance, specifically in the ER-negative subtype." --

Combination Therapy Against Multidrug Resistance

Combination Therapy Against Multidrug Resistance
  • Author : Mohmmad Younus Wani,Aijaz Ahmad
  • Publisher :Unknown
  • Release Date :2020-04-30
  • Total pages :268
  • ISBN : 9780128205785
GET BOOK HERE

Summary : Combination Therapy against Multidrug Resistance explores the potential of combination therapy as an efficient strategy to combat multi-drug resistance. Multidrug resistance (MDR) occurs when microorganisms such as bacteria, fungi, viruses, and parasites are excessively exposed to antimicrobial drugs such as antibiotics, antifungals, or antivirals, and in response the microorganism undergoes mutations or develops different resistance mechanisms to combat the drug for its survival. MDR is becoming an increasingly serious problem in both developed and developing nations. Bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat, and the same is true for a variety of other diseases. Combination therapy proves to be a promising strategy as it offers potential benefits such as a broad spectrum of efficacy, greater potency than the drugs used in monotherapy, improved safety and tolerability, and reduction in the number of resistant organisms. This book considers how combination therapy can be applied in multiple situations, including cancer, HIV, tuberculosis, fungal infections, and more. Combination Therapy Against Multidrug Resistance gathers the most relevant information on the prospects of combination therapy as a strategy to combat multridrug resistance and helping to motivate the industrial sector and government agencies to invest more in research and development of this strategy as a weapon to tackle the multidrug resistance problem. It will be useful to academics and researchers involved in the development of new antimicrobial or antiinfective agents and treatment strtategies to combat multidrug resistance. Clinicians and medical nurses working in the field of infection prevention and control (IPC) will also find the book relevant Explores strategic methods with investigation of both short- and long-term goals to combat multidrug resistance Presents a broad scope to understand fully the ways to apply combined therapy to multidrug resistance Provides an overview of combination therapy, but also includes specific cases such as cancer, tuberculosis, HIV and malaria